Toscafund-led Group Buys Spire Healthcare for £1.03bn

A significant shift is underway in the UK's private healthcare sector as a consortium, spearheaded by Toscafund Asset Management, has successfully negotiated a £1.03 billion (approximately $1.3 billion USD) take-private transaction for Spire Healthcare. This move concludes Spire's ten-year tenure as a publicly traded entity on the London Stock Exchange, signaling a new chapter under private ownership. The acquisition vehicle, operating as Tulip UK Bidco, unites the strategic vision of Toscafund with the financial backing of US investment manager Ares and UK private equity firm Three Hills.

The agreed-upon cash offer of 250 pence per share represents a substantial premium, reflecting a 66.2% uplift compared to Spire's share price prior to the initial approach becoming public. This valuation places Spire's equity at approximately £1,026.5 million, with an implied enterprise value reaching roughly £2.31 billion when factoring in existing debt. The board of Spire Healthcare, through its chair-designate Debbie White, has endorsed the offer, emphasizing that it provides compelling and certain value for shareholders, surpassing all other formal proposals received during the strategic review process.

This transaction is particularly noteworthy given Toscafund's existing substantial shareholding in Spire. Martin Hughes, founder of Toscafund, views this acquisition as an opportunity to support a healthcare business with a long-term perspective, free from the short-term pressures of public markets. The financial structure of the deal is further bolstered by approximately £500 million in debt financing provided by specialist investor Song Capital, underscoring the robust financial commitment behind the acquisition.

Spire Healthcare, a prominent player in the UK's independent healthcare network, operates 38 private hospitals and over 55 clinics across England, Wales, and Scotland. In 2025, the company served approximately 1.36 million patients, catering to both private individuals and the National Health Service (NHS). The move to private ownership is anticipated to unlock greater flexibility in accessing capital, facilitating future growth initiatives and strategic acquisitions within the dynamic healthcare market. This comes after a period of strategic review initiated in September 2025, during which other potential suitors, including Bridgepoint and Triton, engaged in discussions but ultimately did not finalize an offer.

The leadership transition at Spire Healthcare will see Chief Executive Justin Ash depart after a nine-year tenure. Sir David Sloman, a non-executive director and vice-chair, will assume the role of interim chief executive. Sloman brings a wealth of experience from his previous leadership positions within the NHS, including managing multiple NHS trusts and serving as chief operating officer at NHS England. Concurrently, Ian Cheshire will step down as chair, with Debbie White taking over as interim chair. This leadership reshuffling aims to guide the company through its transition into private ownership.

The divestment of Spire's property assets earlier this year, where a portfolio of 12 acute-care hospitals was sold to funds managed by Blue Owl Capital for around £1.3 billion, suggests a strategic move to streamline operations and enhance financial flexibility. This separation of operational assets from real estate positions Spire Healthcare for a focused future under its new ownership, potentially enabling greater investment in service expansion and technological advancements within the UK's growing private healthcare sector, which has seen increased demand for both elective procedures and NHS-contracted services.